Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Multicenter Rollover Study to Provide Continued Treatment to Participants Previously Enrolled in a RVU120 Clinical Study

NCT06987058 is registered in ClinicalTrials.gov with Ryvu Therapeutics SA as lead sponsor.

NCT NCT06987058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06987058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Multicenter Rollover Study to Provide Continued Treatment to Participants Previously Enrolled in a RVU120 Clinical Study
Lead sponsor
Ryvu Therapeutics SA
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
December 4, 2025
Completion date
December 31, 2026
Enrollment
14 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia (aml), advanced solid tumors, high-risk myelodysplastic syndrome